Short-term safety and curative effect of recombinant adenovirus carrying hepatocyte growth factor gene on ischemic cardiac disease

In Vivo

Volumn 22, Issue 5, 2008, Pages 629-632

  Yuan, Biao ^a   Zhao, Zhong ^a   Zhang, You Rong ^b   Wu, Chu Tse ^b   Jin, Wei Guo ^a   Zhao, Sheng ^a   Wangi, Wei ^a   Zhang, Yang Yang ^a   Zhu, Xiao Luan ^a   Wang, Li Sheng ^b   Huang, Jun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Coronary artery bypass; Coronary heart disease (CHD); Gene therapy; Hepatocyte growth factor (HGF)

Indexed keywords

ADENOVIRUS VECTOR; SCATTER FACTOR; UREA;

ADULT; AGED; ANTIANGIOGENIC GENE THERAPY; ARTICLE; CARDIOVASCULAR GENE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE PERFUSION; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTOSIS; LOW DRUG DOSE; MALE; OPEN STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

EID: 53849138775     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Sim EK, Zhang L, Shim WS, Lim YL and Ge R: Therapeutic angiogenesis for coronary artery disease: J Card Surg 17(4): 350-354, 2002.
2. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD and Rasmussen HS: Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 13(21): 1503-1511, 2006.
3. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK and Engler RL: Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105(11): 1291-1297, 2002.
4. Jin H, Wyss JM, Yang R and Schwall R: The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure. Curr Pharm Des 10(20): 2525-2533, 2004.
5. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini P and Rosen EM: Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 90: 1937-1941, 1993.
6. Jayasankar V, Woo YJ, Bish LT, Pirolli TJ, Chatterjee S, Berry MF, Burdick J, Gardner TJ and Sweeney HL: Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation 108(Suppl 1): II230-236, 2003.
7. Li Y, Takemura G, Kosai K, Yuge K, Nagano S, Esaki M, Goto K, Takahashi T, Hayakawa K, Koda M, Kawase Y, Maruyama R, Okada H, Minatoguchi S, Mizuguchi H, Fujiwara T and Fujiwara H: Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 107(19): 2499-2506, 2003.
8. Morishita R, Aoki M, Hashiya N, Makino H, Yamasaki K, Azuma J, Sawa Y, Matsuda H, Kaneda Y and Ogihara T: Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 44(2): 203-2092,004.
9. Wu DL, Zhang YR, Lao MF, Yuan LZ, Wang L, Ha XQ and Wu TC: 1.Wu DL, Zhang YR, Lao MF, Yuan LZ, Wan L, Ha XQ, Wu CT: Therapeutic induction of angiogenesis by direct myocardial administration of an adenovirus vector encoding human hepatocyte growth factor gene and its safety. Chin Sci Bull 49(14): 1464-1469, 2004.
10. Rosengart T and Lee LY: Angiogenesis gene therapy phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100: 468-474,1999.
11. Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK and Crystal RG: Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 13(1): 15-63, 2002.
12. Sim EK, Zhang L, Shim WS, Lim YL and Ge R: Therapeutic angiogenesis for coronary artery disease. J Card Surg 17(4): 350-354, 2002.
13. Grines C, Rubanyi GM, Kleiman NS, Marrott P and Watkins M: Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5 FGF-4): a new option for the treatment of coronary artery disease. Am J Cardiol 92(9B): 24N-31N, 2003.
14. Henry TD, Grines CL, Watkins MW, Dib N, Barbeau G, Moreadith R, Andrasfay T and Engler RL: Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 50(11): 1038-1046,2007.